• news.cision.com/
  • H. Lundbeck A/S/
  • H. Lundbeck A/S' Compound for the Treatment of Anxiety Disorder - Seramesine - Enters Clinical Phase II Release No 26
English

H. Lundbeck A/S' Compound for the Treatment of Anxiety Disorder - Seramesine - Enters Clinical Phase II Release No 26

Report this content

H. Lundbeck A/S hereby announces that seramesine has just initiated clinical phase II studies. Seramesine is a compound for the treatment of anxiety disorder.

Seramesine affects the sigma 2 receptor and in phase I seramesine has proven well tolerated in short of 200 voluntary healthy men and women.

Most of the compounds used today for the treatment of anxiety disorder entail a serious risk of addiction and/or abuse. Seramesine on the contrary is not expected to entail such a risk.

The content of this release will not influence the Lundbeck Group's expectations for the financial result 2000.

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological diseases. It had consolidated net turnover of DKK 4.2 billion in 1999 and employs approximately 2,800 people. 


CONTACT:  Hans Henrik Munch-Jensen,
          Senior Vice President
          Corporate Communications & Investor Relations
          +45 36 30 15 11 ext. 2660

Subscribe